3.93
5.36%
0.20
Precedente Chiudi:
$3.73
Aprire:
$3.73
Volume 24 ore:
949.11K
Relative Volume:
1.21
Capitalizzazione di mercato:
$275.17M
Reddito:
$73.48M
Utile/perdita netta:
$-108.30M
Rapporto P/E:
-1.6653
EPS:
-2.36
Flusso di cassa netto:
$-67.17M
1 W Prestazione:
+13.58%
1M Prestazione:
-16.56%
6M Prestazione:
+193.28%
1 anno Prestazione:
+118.33%
Personalis Inc Stock (PSNL) Company Profile
Nome
Personalis Inc
Settore
Industria
Telefono
650-752-1300
Indirizzo
6600 DUMBARTON CIRCLE, FREMONT, CA
Confronta PSNL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
3.93 | 275.17M | 73.48M | -108.30M | -67.17M | -2.36 |
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-02-06 | Aggiornamento | Needham | Hold → Buy |
2022-01-07 | Aggiornamento | BofA Securities | Neutral → Buy |
2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-11-03 | Downgrade | Needham | Buy → Hold |
2021-10-15 | Ripresa | Cowen | Outperform |
2021-09-20 | Reiterato | Needham | Buy |
2021-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
2021-01-28 | Iniziato | Truist | Buy |
2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
2020-11-12 | Reiterato | Needham | Buy |
2020-11-06 | Downgrade | Oppenheimer | Outperform → Perform |
2020-10-19 | Iniziato | Citigroup | Buy |
2020-10-08 | Iniziato | BTIG Research | Buy |
2020-08-27 | Iniziato | H.C. Wainwright | Buy |
2020-08-18 | Iniziato | Needham | Buy |
2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2019-07-15 | Iniziato | BofA/Merrill | Neutral |
2019-07-15 | Iniziato | Cowen | Outperform |
2019-07-15 | Iniziato | Morgan Stanley | Overweight |
2019-07-15 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Personalis Inc Borsa (PSNL) Ultime notizie
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Personalis CFO Aaron Tachibana sells $4,953 in stock By Investing.com - Investing.com Australia
Personalis SVP sells $6,416 in stock - Investing.com India
Personalis CFO Aaron Tachibana sells $4,953 in stock - Investing.com India
Personalis SVP sells $6,416 in stock By Investing.com - Investing.com Nigeria
Personalis to Participate at Upcoming Investor Conferences - The Bakersfield Californian
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Personalis, Inc. (NASDAQ:PSNL) Shares Sold by GSA Capital Partners LLP - MarketBeat
Personalis Inc. (PSNL) Quarterly 10-Q Report - Quartzy
FY2024 EPS Estimates for Personalis Cut by HC Wainwright - MarketBeat
FY2024 EPS Estimate for Personalis Decreased by Analyst - Defense World
Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation - Yahoo Finance
Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Q3 2024 Earnings Call Transcript - Insider Monkey
FY2028 EPS Estimates for Personalis Cut by HC Wainwright - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Shares Bought by ARK Investment Management LLC - MarketBeat
International Assets Investment Management LLC Has $113,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Key Takeaways From Personalis Analyst Ratings - Benzinga
Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust R - GuruFocus.com
Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ... - Yahoo Finance
Needham & Company LLC Reiterates Buy Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Don't Ignore The Insider Selling In Personalis - Simply Wall St
What Analysts Are Saying About Personalis Stock - Benzinga
Earnings call: Personalis Q3 2024 results show robust biopharma growth - Investing.com
Personalis Reports Solid Q3 Growth and Raises Revenue Outlook - TipRanks
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates - MSN
Personalis: Q3 Earnings Snapshot - San Francisco Chronicle
Personalis to Present at the Stifel 2024 Healthcare Conference - Marketscreener.com
Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To E - GuruFocus.com
Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Institutional investors have a lot riding on Personalis, Inc. (NASDAQ:PSNL) with 37% ownership - Simply Wall St
Personalis (PSNL) Set to Announce Earnings on Wednesday - MarketBeat
The Proper Play On Personalis (NASDAQ:PSNL) - Seeking Alpha
Personalis to Announce Third Quarter 2024 Financial Results - Business Wire
Personalis Inc (PSNL) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Dimensional Fund Advisors LP Trims Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Was there any good news for Personalis Inc (PSNL) stock in the last session? - US Post News
PSNL’s latest rating updates from top analysts. - Knox Daily
Personalis Inc (PSNL) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Was anything negative for Personalis Inc (PSNL) stock last session? - US Post News
Personalis Inc [PSNL] Insider Activity: An Update for Investors - Knox Daily
Personalis Inc [PSNL] Shares Fall -2.23 % on Wednesday - Knox Daily
Wall Street analysts’ outlook for Personalis Inc (PSNL) - SETE News
Personalis Inc: Navigating a Turbulent Year, Up -31.53% from 52-Week Low - The InvestChronicle
Cancer test developer Personalis to cut 65 jobs to reduce costs - MSN
Investing in Personalis Inc (PSNL): What You Must Know - Knox Daily
Metric Deep Dive: Understanding Personalis Inc (PSNL) Through its Ratios - The Dwinnex
Personalis Inc (PSNL) stock analysis: A simple moving average approach - US Post News
The growth track for Personalis Inc (PSNL) has changed recently - SETE News
Personalis Inc: Weathering Stock Market Storms with 269.46M Market Cap - The InvestChronicle
Personalis Inc Azioni (PSNL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Personalis Inc Azioni (PSNL) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Moore Stephen Michael | SVP and Chief Legal Officer |
Nov 18 '24 |
Sale |
3.79 |
1,693 |
6,416 |
67,388 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Nov 18 '24 |
Sale |
3.79 |
921 |
3,491 |
128,720 |
Hall Christopher M | PRESIDENT AND CEO |
Nov 01 '24 |
Sale |
5.38 |
26,443 |
142,263 |
178,098 |
Tempus AI, Inc. | 10% Owner |
Aug 16 '24 |
Buy |
5.07 |
3,500,000 |
17,745,000 |
12,718,800 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jul 30 '24 |
Sale |
2.97 |
524 |
1,556 |
127,227 |
Tachibana Aaron | CFO AND COO |
Jul 30 '24 |
Sale |
2.97 |
742 |
2,204 |
175,270 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jun 17 '24 |
Sale |
1.29 |
5,055 |
6,521 |
127,751 |
Tachibana Aaron | CFO AND COO |
Jun 17 '24 |
Sale |
1.29 |
7,176 |
9,257 |
176,012 |
Moore Stephen Michael | SVP and Chief Legal Officer |
Jun 17 '24 |
Sale |
1.29 |
1,585 |
2,045 |
69,081 |
Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 17 '24 |
Sale |
1.38 |
940 |
1,297 |
132,806 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):